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Abstract
Background: Toll-like receptors (TLRs) play an essential role in the innate immune system by
initiating and directing immune response to pathogens. TLRs are expressed in the human
endometrium and their regulation might be crucial for the pathogenesis of endometrial diseases.
Methods:  TLR3 and TLR4 expression was investigated during the menstrual cycle and in
postmenopausal endometrium considering peritoneal endometriosis, hyperplasia, and endometrial
adenocarcinoma specimens (grade 1 to 3). The expression studies applied quantitative RT-PCR and
immunolabelling of both proteins.
Results: TLR3 and TLR4 proteins were mostly localised to the glandular and luminal epithelium.
In addition, TLR4 was present on endometrial dendritic cells, monocytes and macrophages. TLR3
and TLR4 mRNA levels did not show significant changes during the menstrual cycle. In patients with
peritoneal endometriosis, TLR3 and TLR4 mRNA expression decreased significantly in proliferative
diseased endometrium compared to controls. Interestingly, ectopic endometriotic lesions showed
a significant increase of TLR3 und TLR4 mRNA expression compared to corresponding eutopic
tissues, indicating a local gain of TLR expression. Endometrial hyperplasia and adenocarcinoma
revealed significantly reduced receptor levels when compared with postmenopausal controls. The
lowest TLR expression levels were determined in poor differentiated carcinoma (grade 3).
Conclusion: Our data suggest an involvement of TLR3 and TLR4 in endometrial diseases as
demonstrated by altered expression levels in endometriosis and endometrial cancer.
Background
Toll-like receptors (TLRs) recognize specific pathogen
associated molecular patterns (PAMPs) and serve an
essential role in the innate immune system by initiating
and directing immune response to microbial pathogens.
Human TLRs comprise a large family of 10 proteins with
member-specific activators and a complex downstream
signalling [1]. TLRs are expressed on various immune cells
but are also present on mucosal surfaces of the respiratory,
gastrointestinal and urinary tract [1]. Applying different
adaptor proteins such as toll-like receptor adaptor mole-
cule 1 (TRIF, TICAM1), myeloid differentiation primary
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response gene 88 (MyD88), myelin and lymphocyte pro-
tein Mal, translocation associated membrane protein
(TRAM) and sterile alpha and TIR motif containing
(SARM), TLRs activate signalling pathways of mitogen-
activated protein kinases, nuclear factor kappa-B (NFêB),
signal transducers and activators of transcription (STATs)
or the activator protein 1 (AP1) [1-3]. These signalling cas-
cades result in enhanced secretion of various pro- and
anti-inflammatory cytokines such as interferons, tumor
necrosis factor α (TNFα) and interleukins IL4, IL8, and
IL12 [1,2]. Two studies have described the expression of
human TLRs in epithelial cells within the female repro-
ductive tract [4,5]. Other than their importance for the
interaction between host and pathogen, the receptors
might be involved in mucosal homeostasis as described
already for the intestine and colon [6]. TLR3 is implicated
in the recognition of dsRNA, mRNA and viruses [1,7],
whereas TLR4 is a key component of the initial injury
response by reacting towards bacterial endotoxin and
multiple endogenous ligands [8]. Recent studies have
determined the expression pattern of TLR3 [4,9-12] and
TLR4 [4,10-14] in the human endometrium, but their
possible involvement in the pathogenesis of endometrial
diseases associated with inflammation remains to be elu-
cidated.
Endometriosis is a common benign gynaecological condi-
tion of reproductive aged women [reviewed in [15]]. The
disease is characterised by endometrial tissue fragments
outside the uterine cavity and is associated with pelvic
pain, dysmenorrhoea, and infertility. Since aetiology and
pathogenesis remain uncertain, different theories are dis-
cussed including altered immune function. The deregula-
tion of immune response in endometriosis is
characterised by increased number of activated macro-
phages and their secreted products, such as growth factors,
cytokines, and angiogenic factors [16,17]. Young et al.
reported an increase in interleukin-8 (IL-8) production
after stimulating TLR3 and TLR4 in endometrial cell lines
with appropriate ligands [12]. IL-8 is a chemotactic acti-
vating cytokine for leukocytes and it has been hypothe-
sized to play a role in the growth and maintenance of
ectopic endometrial tissue [18]. Recent studies consider
endometriosis as a process of sterile inflammation in the
pelvis, which is accompanied by elevated levels of inflam-
matory key regulators such as TNFα [19] or NF-κβ [20].
Both are known downstream targets of TLRs.
Endometrial carcinoma is the most common gynaecolog-
ical malignancy in Europe and North America affecting
mainly postmenopausal women [21]. In endometrial
tumorigenesis, two different types are characterised: the
estrogen-related adenocarcinoma (endometrioid type)
and the non-endometrioid type such as papillary serous
and clear cell carcinoma [21]. Adenocarcinoma accounts
for seventy percent of endometrial cancer and is mostly
preceded by premalignant changes like endometrial
hyperplasia [21]. The majority of adenocarcinoma
expresses steroid receptors and occur in women with risk
factors associated with an imbalance of estrogen and pro-
gesterone. However, inflammation with production of
pro-inflammatory cytokines such as TNFα is known to
play an important role in cancer development [22]. In
endometrial hyperplasia and adenocarcinoma the expres-
sion of NFκB and TFNα has been demonstrated [23] indi-
cating that the production of pro-inflammatory cytokines
seem to play a role in endometrial tumorigenesis.
The present study describes the expression pattern of TLR3
and TLR4 mRNA and proteins in healthy endometrium
across the menstrual cycle and in postmenopausal tissue.
To assess the possible involvement of these toll-like recep-
tors in endometrial pathologies, their expression pattern
was also examined in endometriosis and in adenocarci-
noma specimens.
Methods
Endometrial tissues
Endometrial tissues were obtained from 55 women with
regular menstrual cycles (mean 28 ± 2.2 days) who were
undergoing gynaecological procedures for benign condi-
tions at the Department of Gynaecology, University Hos-
Table 1: Patients' characteristics according to diagnosis at time of surgery
n Age, mean Age, SD Indications for surgery
Premenopausal, controls (proliferative & secretory) 27 37 8.6 fibroids (n = 7), non endometriotic ovarian cyst (n = 2), 
infertility (n = 5), dysmenorrhoe (n = 11), pelvic pain (n = 1), 
uterine prolapse (n = 1)
Premenopausal, non-endometriotic, menstrual 8 39 10.7 no surgery
Premenopausal, endometriotic 20 34 6.8 endometriosis (n = 11), ovarian cyst (n = 2), infertility (n = 1), 
dysmenorrhoe (n = 6*)
Postmenopausal, controls 8 68 10.2 fibroids (n = 6), uterine prolapse (n = 2)
Postmenopausal, hyperplasia 10 64 13 abnormal endometrial thickness, supposed carcinoma
Postmenopausal, endometrial carcinoma 16 67 12.8 abnormal endometrial thickness, endometrial carcinoma
n = number of patients, * not including patients with known endometriosis before surgeryReproductive Biology and Endocrinology 2008, 6:40 http://www.rbej.com/content/6/1/40
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pital Essen (table 1). In this cohort, 20 women have been
diagnosed with endometriosis. Menstrual effluents were
collected from women without proven endometriosis
during first three days of menstrual bleeding as described
elsewhere [24].
The menstrual cycle phase was characterised by morpho-
logic evaluation following the criteria of Noyes et al. [25]:
proliferative (P, controls: n = 16, endometriotic: n = 13),
secretory (S, controls: n = 11, endometriotic: n = 3) and
menstrual (M, n = 8) phase. Additionally, four prolifera-
tive corresponding ectopic lesions were included,
obtained from the above-characterised cohort. In the pre-
menopausal group, patient age ranged from 19 to 52 years
(median: 38, detailed data in table 1).
Postmenopausal endometrium was obtained from 34
women including 10 with endometrial hyperplasia and
another 16 with endometrial carcinoma (table 1). The
remaining 8 patients did not have any endometrial abnor-
malities and were used as the control group. Patients were
considered postmenopausal if they have been in meno-
pause for at least one year. Endometrial adenocarcinoma
specimens were classified based on the post-operative his-
topathologic WHO guidelines [26] as follow: grade 1 (G1,
well differentiated, n = 5), G2 (moderately differentiated,
n = 6), G3 (undifferentiated, n = 5). In the postmenopau-
sal group, patient age ranged from 37 to 86 years (median:
66).
None of the women included in the studies had received
any hormonal treatments for at least three months preced-
ing biopsy and routinely analyzed laboratory parameters
from blood samples were physiologically analogous to
the patient's age. Considering the leukocyte content and
level of C-reactive protein, no systemic inflammation was
diagnosed at the time of surgery. Volunteers donating
menstrual effluents were healthy and without diagnosed
infections.
Institutional ethical approval was granted for all subjects,
and all women provided written informed consent.
All biopsies were transferred into a buffered saline solu-
tion directly after surgery and stored in this buffer for max-
imal two hours until further use. A portion of the biopsy
specimen was fixed in 4% formalin and embedded in par-
affin for histology and immunohistochemistry, the
remainder was flash-frozen in liquid N2 for RNA extrac-
tion.
Quantitative real-time PCR
Isolation of total RNA from endometrial tissue and
reverse transcription into cDNA were carried out applying
standard methods as described previously [24]. Following
a DNase digest and reverse transcription, quantitative
real-time PCR (qPCR) reactions were performed in tripli-
cates using an ABI Prism 7300 Sequence Detector
(Applied Biosystems, Weiterstadt, Germany) in a total
volume of 20 μl containing 40 ng cDNA, 3.75 pmol gene-
specific primers (table 2) and SYBR Green reagent
(Applied Biosystems) with ROX dye as passive control for
signal intensity. The thermal cycle profile was 10 sec at
95°C, followed by 45 cycles of 5 sec at 95°C and 35 sec at
60°C. Melting curve analysis allowed determination of
the specificity of the PCR fragments. All melting curves
yielded one peak per PCR product.
To determine the copy number of PCR fragments, serially
diluted, gene specific standard cDNAs generated from
amplicons of TLR3, TLR4 and β-actin (ACTB) were used.
Applying thermal block cyclers and ethidium bromide gel
electrophoresis, standard PCRs were conducted. Each
gene-specific PCR resulted in one distinct band of the
appropriate length. The amplicons were purified by using
a Qiagen kit and cDNA concentration was measured pho-
tometrically. For each gene, five different dilutions of
standard cDNA were used in real time PCR. Threshold
cycles for TLR3 signals were between 26 and 38 and for
TLR4 between 25 and 36, respectively. Because of the
diversity in the RNA quality, each individual sample was
normalized to its ACTB mRNA content as an internal
standard. These relative values were used for statistics.
Immunohistochemistry
Paraffin-embedded specimens were sectioned at 7 μm,
rehydrated and microwaved in 0.01 M sodium citrate
buffer, pH 6.0, for 10 min for antigen retrieval. Immunos-
tainings were performed on paraffin sections applying the
diaminobenzidine staining method with the
VECTASTAIN Elite ABC kit (Vector Laboratories, Burlin-
game, CA) according to the manufacturer's protocol.
Table 2: Oligonucleotide primers used for the quantitative real time PCR.
Gene (GenBank No.) Forward primers (position) Reverse primers (position)
TLR3 (NM_003265) 5'-GTATTGCCTGGTTTGTTAATTGG (2059–2082) 5'-AAGAGTTCAAAGGGGGCACT (2215–2194)
TLR4 (NM_138557) 5'-AAGCCGAAAGGTGATTGTTG (2187–2206) 5'-CTGAGCAGGGTCTTCTCCAC (2339–2320)
ACTB (NM_001101) 5'-ACCAACTGGGACGACATGGA (302–322) 5'-CCAGAGGCGTACAGGGATAG (510–491)
All primers were designed using the Primer3 software.Reproductive Biology and Endocrinology 2008, 6:40 http://www.rbej.com/content/6/1/40
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Endogenous peroxidase activity was quenched with 0.3%
H2O2 in methanol for 10 minutes and washed in buff-
ered saline solution (PBS). Unspecific binding of the first
antibody was blocked by 30-minute incubation step in
PBS containing 0.15% normal horse serum. Slides were
incubated in a humidified chamber overnight at 4°C with
the monoclonal mouse-anti-human antibodies against
TLR3 [27] and TLR4 [HTA125, [28]] at 20 μg/ml and 100
μg/ml, respectively (Acris Antibodies, Hiddenhausen,
Germany). Control samples were carried out by omitting
the primary antibody. All sections were counterstained
with haematoxylin and documented by using a Zeiss Axi-
ophot microscope (Zeiss, Jena, Germany) with a Nikon
DS-U1 camera and the LUCIA Image Analysis software
(Nikon, Tokyo, Japan).
Immunofluorescent staining
Frozen tissues were sectioned at 7 μm and fixed in 70%
ethanol. Unspecific binding of the first antibody was
blocked by a 30 min incubation step in 5% BSA/PBS. The
TLR4 antibody was incubated as described above and was
detected using Alexa Fluor 488-conjugated anti-mouse
antibody (3.3 μg/ml, MoBiTec, Goettingen, Germany).
Sections were fixed in formalin (4%) for two minutes and
then washed in PBS. The incubations with CD14 (10 μg/
ml, mouse anti-human, BioLegend, San Diego, CA) or
CD163 (10 μg/ml, mouse anti-human, HyCult Biotech-
nology, Uden, The Netherlands) occurred at room tem-
perature for 60 min. CD14 antigen is expressed on on
monocytes/macrophages, acting as a dendritic cells pre-
cursor [29]. CD163 is a member of the scavenger receptor
cystein-rich family class B and is expressed on most sub-
populations of mature tissue macrophages [30]. CD163 is
highly abundant in human placenta [31] and is present in
shed menstrual endometrium [24]. The secondary, goat
anti-mouse antibody was Cy3-conjugated (2.5 μg/ml,
Dianova, Munich, Germany) and was applied to the spec-
imens for another 60 minutes. Nuclei were identified by
4',6'-diamidino-2-phenylindole staining (DAPI, Sigma,
Munich, Germany) using 0.1 μg/ml DAPI in methanol for
15 min at 37°C. Negative controls were performed by
omitting the primary antibody and were used to adjust the
background fluorescence.
After mounting with Mowiol (Sigma), confocal micros-
copy was performed using a Zeiss Axiovert 100 micro-
scope and LSM 510 system (Zeiss, Jena, Germany). TLR4
was detected at 488 nm, CD14 as well as CD163 at 543
nm, and DAPI at 366 nm, respectively.
Statistical analysis
Exploratory data analyses, Kruskal-Wallis test for group
comparisons, as well as the Mann-Whitney U test for non-
parametric independent two-group comparisons were
performed with the program SPSS 14 for Windows (SPSS
Inc., Chicago, IL). Differences with P < 0.05 were regarded
as statistically significant, P < 0.01 as highly statistically
significant. Values of mRNA quantification are given as
mean ± standard deviation (SD).
Results
TLR3 and TLR4 expression is deregulated in peritoneal 
endometriosis
Both receptors were expressed in all endometrial biopsies
with the averaged TLR4 mRNA levels being higher (20-
fold) than TLR3 (figure 1). This difference was the greatest
in the shed menstrual endometrium, where TLR4 tran-
scripts were 564-fold higher than those for TLR3. The rel-
ative abundance of both transcripts did not vary
throughout the menstrual cycle (figure 1).
TLR3 and TLR4 proteins were expressed mainly in the
luminal and glandular epithelium (figure 2). Interest-
ingly, the glands presented a heterogeneous immune
staining for TLR3 (figure 2C, I). Indeed, the TLR3 receptor
was found to be locally expressed in a subset of epithelial
cells within one gland. In addition, we report the expres-
sion of TLR4 protein on immune cells such as monocytes
and macrophages, in menstrual phase samples (figure 2J).
Co-immunostainings on menstrual effluents confirmed
that CD14 positive dendritic cells and monocytes (figure
2K) as well as CD163 positive resident macrophages (fig-
ure 2L) expressed TLR4 protein.
TLR3 and TLR4 transcript are expressed in endometrium  during the menstrual cycle Figure 1
TLR3 and TLR4 transcript are expressed in 
endometrium during the menstrual cycle. Columns 
indicate mean TLR3 and TLR4 mRNA quantities from 
endometrium in proliferative (n = 16), secretory (n = 11) and 
menstrual phase (n = 8) run in triplicates. The y-axis is scaled 
logarithmically; error bars represent the standard deviation 
of the mean.Reproductive Biology and Endocrinology 2008, 6:40 http://www.rbej.com/content/6/1/40
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In endometriosis, we can observe a significant decrease in
TLR3 and TLR4 mRNA levels in eutopic tissues collected
during the proliferative phase, when compared to controls
(P  < 0.05; figure 3A–B). Interestingly, endometriotic
lesions in proliferative phase showed a significant
increase of TLR3 mRNA expression (P < 0.05) when com-
pared with the corresponding eutopic endometrium (fig-
ure 3A). For the TLR4 transcript, a 6-fold increase was
observed in the endometriotic lesions in comparison with
the diseased eutopic endometrium (P < 0.01; figure 3B).
In the endometrial tissues collected during the secretory
phase, the TLR4 mRNA level tended to be lower in eutopic
endometrium than in controls (P = 0.08; figure 3D).
Immunostaining analyses confirmed these findings at the
protein level. In endometriosis, eutopic tissues revealed
weaker staining for TLR3 and TLR4 proteins (figure 2B, D,
F, H) when compared to controls (figure 2A, C, E, G). Fig-
ure 4 exemplary presents the expression of TLR3 and TLR4
protein in eutopic compared to ectopic endometrium
from the same patient. The TLR3 (Fig. 4A) and TLR4 (Fig.
4C) immunostaining in diseased eutopic endometrium
was barely detectable, whereas corresponding lesion from
the uterosacral ligament showed an intense staining in the
glandular epithelium for both proteins (Fig. 4B and 4D).
Concerning protein localization, we found TLR3 and
TLR3 and TLR4 protein is localised to endometrial cells during the menstrual cycle Figure 2
TLR3 and TLR4 protein is localised to endometrial cells during the menstrual cycle. TLR3 protein staining in 
healthy late proliferative (LP) tissue was high in luminal and glandular tissue (A, brown precipitate) and lower in LP endometri-
otic tissue (B). Late secretory (LS) endometrium showed highly expressed TLR3 in the epithelium (C), but weakly in endome-
triosis (D). Intense staining of TLR4 proteins was shown in mid proliferative (MP) tissue (E). In late proliferative phase of 
endometriosis, TLR4 proteins were comparably lower (F). TLR4 protein was high in mid secretory (MS) normal endometrium 
(G), whereas it was decreased in endometriotic MS tissue (H). During the menstrual phase, both TLR3 (I) and TLR4 (J) were 
highly expressed. Co-immunostaining for TLR4 (green), CD14 (K, red) and CD163 (L, red) demonstrated that TLR4 proteins 
were expressed by CD14 positive dendritic cells and monocytes (K, yellow) and by CD163 positive macrophages (L, yellow). 
Localisation of TLR4 to immune cells is marked by a black arrow (J) and by white arrows (K, L).Reproductive Biology and Endocrinology 2008, 6:40 http://www.rbej.com/content/6/1/40
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TLR4 proteins in glandular and epithelial cells of endome-
triosis patients.
TLR3 and TLR4 are expressed in postmenopausal 
endometrium and regulated endometrial adenocarcinoma
TLR3 and TLR4 mRNA abundance in healthy postmeno-
pausal tissues is similar to those found during the men-
strual cycle. In postmenopausal controls, TLR4 mRNA
levels were higher than those for TLR3 (P < 0.05, figure 5).
TLR3 and TLR4 mRNA expression varied significantly
between control, hyperplasia and endometrial adenocar-
cinoma samples (Kruskal-Wallis test, P < 0.01). For both
receptors, we observe a significant decrease in mRNA
abundance in endometrial hyperplasia and adenocarci-
noma samples, when compared to postmenopausal
endometrium (P < 0.05; figure 5A–B). In undifferentiated
G3 carcinoma, TLR3 and TLR4 mRNA levels were signifi-
cantly lower than in postmenopausal controls (P < 0.01)
and in hyperplasic endometrial tissues (P < 0.05, figure
5C–D).
TLR3 and TLR4 proteins in hyperplasia and endometrial
carcinoma were mostly localized to the luminal and glan-
dular epithelium (figure 6). Additionally, we demonstrate
a discontinuous staining for TLR3 protein within epithe-
lial glands of G1 carcinoma (figure 6C), comparable to
the findings in secretory and menstrual phase of premen-
opausal women (figure 2C, I). In undifferentiated G3 car-
cinoma, staining for TLR3 (figure 6E) and TLR4 (figure 6J)
was not detectable, strengthening our findings of low
TLR3 and TLR4 mRNA abundance in G3 carcinoma (fig-
ure 5B). In accordance with staining patterns obtained
during the menstrual phase (figure 2J), we were able to
find TLR4 protein localized on immune cells (figure 6F, G,
H, I). We performed co- immunostainings on controls
and on malignant endometrial tissues (G2 carcinoma)
with antibodies for CD14 and CD163 (figure 7). TLR4
protein was expressed on CD14 positive dendritic cells,
and monocytes (figure 7A, C), as well as on CD163 posi-
tive macrophages (figure 7B, D).
TLR3 and TLR4 mRNA expression is regulated in endometri- osis Figure 3
TLR3 and TLR4 mRNA expression is regulated in 
endometriosis. The expression of TLR3 (A, C) and TLR4 
mRNA (B, D) in endometrium during proliferative (n = 13, 
run in triplicates, A, B) and secretory phase (n = 3, C, D) 
was decreased in eutopic endometriotic endometrium when 
compared to controls. In addition, four proliferative corre-
sponding lesions were evaluated (A, B) showing a local 
upregulation of both receptors on ectopic sites. Columns 
represent the mean ratio of TLR copy number to ACTB 
copy number. Error bars represent the standard deviation of 
the mean. * P < 0.05; ** P < 0.01.
TLR3 and TLR4 protein is locally induced in endometriotic  lesions Figure 4
TLR3 and TLR4 protein is locally induced in endome-
triotic lesions. No specific TLR3 protein staining was seen 
in eutopic endometriotic tissue (A) whereas a high glandular 
localisation of the protein was detected in a gland of an 
ectopic endometriotic lesion from the same patient (B). Sim-
ilarly, TLR4 was not detectable in eutopic endometrium (C) 
but present in glandular epithelium of ectopic endometrium 
from the same women (D).Reproductive Biology and Endocrinology 2008, 6:40 http://www.rbej.com/content/6/1/40
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Discussion
In the current study, we report that toll-like receptor 3 and
4 expression is modulated in pathogenic alterations of the
endometrium. We also found higher TLR4 expression lev-
els in endometrial samples throughout the menstrual
cycle and in postmenopausal biopsies, when compared to
those for TLR3. In most tissues including gut, gonads and
placenta, TLR3 is greater expressed than TLR4 mRNA [32].
TLR3 recognizes RNA and viruses, whereas TLR4 mediates
the response to bacterial endotoxins and is activated due
to sterile inflammation [33,34]. Thus, the predominant
expression of TLR4, observed in uterine tissues, might
reflect the occurrence of sterile inflammation during the
menstrual cycle. Moreover, ascending bacterial pathogens
could contribute to the TLR4 dominance in the uterus.
In agreement with earlier reports [4,12], both investigated
TLRs were mainly localized in the endometrial epithe-
lium, the site of primary immune response in the uterus.
In addition, we were able to detect TLR4 protein on
endometrial CD14 and CD163 positive immune cells. We
found CD14 mainly expressed within the epithelial layer,
only a sporadic number of CD14 positive cells was
detected in stromal compartment, probably representing
the population of monocytes. A recent study performed
on bovine endometrial cells, co-localised TLR4 transcripts
TLR3 and TLR4 mRNA expression is decreased in endometrial adenocarcinoma Figure 5
TLR3 and TLR4 mRNA expression is decreased in endometrial adenocarcinoma. (A-B) Columns indicate mean 
TLR3 (A) and TLR4 (B) mRNA levels from postmenopausal patients (PMP, n = 8), and those diagnosed with endometrial 
hyperplasia (HP, n = 10) and endometrial carcinoma (EnCa, n = 16). (C-D) TLR3 (C) and TLR4 (D) mRNA expression in dif-
ferent carcinoma grades compared to postmenopausal controls and hyperplastic endometrium: G1 (n = 5), G2 (n = 6) and G3 
(n = 5). Error bars represent the standard deviation of the mean. * P < 0.05; ** P < 0.01.Reproductive Biology and Endocrinology 2008, 6:40 http://www.rbej.com/content/6/1/40
Page 8 of 11
(page number not for citation purposes)
with CD14 mRNA and protein to stromal and epithelial
cells [35]. CD14 is a known accessory molecule for TLR4
and conducts a downstream signalling cascade via MyD88
[3]. In agreement with Pioli et al., who detected TLR4,
CD14 and MyD88 transcripts in human endometrium
[14], we were able to co-localize TLR4 with CD14 proteins
suggesting the presence of both interacting receptors
CD14 and TLR4 in the endometrial cells.
For the first time, we present endometrial effluents
expressing high levels of TLR3 and TLR4 proteins. Since
the period of menstruation is accompanied by an
increased risk of infections due to ascending microorgan-
isms [36], we believe that the increased expression of toll-
like receptors may be one of the defense mechanisms used
by the uterus. Previous studies reported that toll-like
receptors are also implicated in epithelial repair as
described for intestinal [6] and alveolar epithelial cells
[37]. In damaged tissue, necrosis induced inflammation is
thought to trigger danger signals, leading to tissue repair
response through TLRs [6]. Since repair processes occur
every month in the uterus of premenopausal women, we
believe that the interaction between hyaluronan and TLR4
might promote the endometrial repair. Hyaluronan is
released by necrotic cells, interacts with TLR4 and acti-
vates CD44 mediated signalling [38]. In the
endometrium, deposition of hyaluronan has been
described in stromal compartment [39]. Moreover,
hyaluronan has been reported to be involved in attach-
ment of endometrial cells to the mesothelium as a very
early step of endometriosis [40]. Further investigations of
hyaluronan-TLR4 signalling in healthy and diseased
endometrium would be of interest to gain insight into the
functional role of TLR4 expression in the uterus.
Endometriosis causes chronic inflammatory conditions in
the pelvic cavity and in the uterus. This disorder is dis-
cussed to be accompanied by an activation of the Th2 type
of immune response and a shift from Th1 towards Th2
cytokine production [41]. Interestingly, Th2 cytokines
were shown to play an important role in balancing TLR
signalling in human intestinal epithelial cells by mediat-
ing downregulation of TLR3 and TLR4 expression and
function [42]. This could also be the case in the diseased
eutopic endometrium, where decreased TLR levels were
found. It remains to be fully elucidated, if deregulation of
TLR expression is involved in the pathogenesis of
endometriosis or if altered TLR expression patterns are a
consequence resulting from the presence of endometriotic
lesions. We could recently show that uterine gene expres-
sion patterns are altered due to the existence of ectopic
lesions in a non-human primate model for endometriosis
[43,44]. Since implantation is a process accompanied by
an inflammatory event, an impaired fertility observed in
endometriotic women could be one consequence [45].
Continued studies are needed to determine the role of
TLR function in diseased endometrium, which could be a
promising path towards a better understanding of the
pathogenesis of this disease.
Interestingly, we found a local upregulation of both TLRs
in peritoneal endometriotic lesions when compared to
TLR3 and TLR4 proteins are present in postmenopausal endometrium Figure 6
TLR3 and TLR4 proteins are present in postmenopausal endometrium. Localisation of TLR3 in normal postmeno-
pausal endometrium (A), endometrial hyperplasia (B), endometrial adenocarcinoma grade G1 (C), G2 (D) and G3 (E). Local-
isation of TLR4 protein in normal postmenopausal endometrium (F), endometrial hyperplasia (G), endometrial 
adenocarcinoma grade G1 (H), G2 (I) and G3(J). All stained sections indicated epithelium as the preferred localisation of 
TLR3 and TLR4 proteins. TLR4 protein was additionally present in immune cells (arrows).Reproductive Biology and Endocrinology 2008, 6:40 http://www.rbej.com/content/6/1/40
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eutopic endometriosis from the same patients. A recent
study presented a local upregulation of CD14 and CD163
in ovarian endometriotic lesions [46]. However, we
observe locally gained TLR4 expression in epithelial cells
as demonstrated in immunohistochemical stainings. We
propose that the sterile inflammation process, which
occurs in the pelvic cavity upon endometriosis, is able to
enhance the epithelial TLR4 expression and thus activate
TLR4 is localised to immune cells of postmenopausal endometrium Figure 7
TLR4 is localised to immune cells of postmenopausal endometrium. Co-Immunostaining of TLR4 with CD14 and 
CD163 in healthy endometrium (A, B) and in adenocarcinoma (C, D). TLR4 proteins were expressed by CD14 positive den-
dritic cells and monocytes (A, C) and by CD163 positive macrophages (B, D). Arrows indicate the co-localisation of TLR4 
with the immune cells. Scale bar = 20 μm.Reproductive Biology and Endocrinology 2008, 6:40 http://www.rbej.com/content/6/1/40
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the known downstream signalling cascade. One of the
potentially activated TLR-downstream molecules is NF-
κB, which was recently found as constitutively elevated in
endometriotic lesions [20]. It is established that the acti-
vation of NF-κB is linked to proliferation, angiogenesis
and enhanced production of inflammatory cytokines on
ectopic sites [17]. Hence, the TLR-NF-κB cascade might
contribute to the chronic persistence of endometriotic
lesions.
In endometrial adenocarcinoma, expression levels of the
downstream molecules TNFα and NF-κB were decreased
in G2 and G3 but not in the well-differentiated grade 1
carcinoma [47]. Although the evidence is lacking, the
almost negligible levels of both toll-like receptors in G3
endometrial adenocarcinoma may reflect lowered differ-
entiation and possibly indicates poor prognosis.
Both endometriosis and endometrial adenocarcinoma are
estrogen dependent diseases. In both conditions, TLR3
and TLR4 were significantly decreased in diseased
endometrium when compared to age matched controls.
However, it is known that estrogen did not influence the
expression of either TLR3 [48] nor TLR4 [49,50] in epithe-
lial cells of endometrium [48], retina [50] and in macro-
phages [49]. Thus, additional factors are required to
decrease TLR-expression in endometriotic endometrium
and in endometrial carcinoma.
Besides excessive estrogen, genetic predisposition presents
one of the risk factors associated with the development of
endometrial adenocarcinoma. In our study, we observed
high inter-individual differences in TLR expression as mir-
rored by high standard deviations. The results implicate a
possible impact of polymorphisms on mRNA expression
in physiologic and pathologic endometrium. Recently, a
functional polymorphism of the TLR4 gene, associated
with impaired TLR signalling, was considered as a signifi-
cant risk factor for gastric carcinoma [51]. Another single
nucleotide polymorphism in 3'-untranslated region of the
same gene has been associated with increased risk for
prostate carcinoma [52]. It remains to be fully elucidated,
if genetic polymorphisms in genes encoding for toll-like
receptors might promote endometrial carcinogenesis.
Conclusion
Our data suggest an involvement of TLR3 and TLR4 in
endometrial diseases as we demonstrated altered expres-
sion levels for both receptors in endometriosis and
endometrial adenocarcinoma. Healthy and differentiated
endometrium seems to require an adequate TLR3 and
TLR4 expression. Further studies are necessary to investi-
gate the potential function of both receptors in endome-
trial diseases.
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